TITLE

Siga files application for emergency use of antiviral drug

PUB. DATE
May 2008
SOURCE
PharmaWatch: Biotechnology;May2008, Vol. 7 Issue 5, p10
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article reports on the submission of an application by Siga Technologies Inc. to support an emergency use authorization of its orally active, smallpox antiviral drug ST-246. The emergency use authorization mechanism enables the U.S. Food and Drug Administration (FDA) Commissioner to authorize the use of a drug that has not been approved, or has not been approved for a particular use, when the nation is in a state of declared emergency.
ACCESSION #
31962421

 

Related Articles

  • Decisions Update.  // PharmaWatch: Biotechnology;Jun2007, Vol. 6 Issue 6, p12 

    The article offers drug approval updates for products of companies in the biotechnology industries in 2007. Sirion Therapeutics Inc. has received orphan drug designation from the U.S. Food and Drugs Administration for its anti-viral therapy ganciclovir, for the treatment of acute herpetic...

  • FAST Act Would Provide Patients with Accelerated Access to Innovative Therapies.  // Biomedical Market Newsletter;3/7/2012, Vol. 21, p1 

    The article offers information related to Faster Access to Specialized Treatments (FAST) Act which helps in accelerating the approval process at the U.S. Food and Drug Administration. It further informs that this Act will enable biotech companies to bring new, safe and effective treatments and...

  • Dolutegravir Tablets (Tivicay®). Elliott, William T.; Chan, James // Internal Medicine Alert;9/15/2013, Vol. 35 Issue 17, p133 

    In this article, the author discusses dosage, potential advantages and disadvantages and clinical implications of the Dolutegravir Tablets.

  • Sofosbuvir: First Global Approval. Keating, Gillian; Vaidya, Asha // Drugs;Feb2014, Vol. 74 Issue 2, p273 

    Sofosbuvir (Solvadiâ„¢), a nucleotide analogue hepatitis C virus NS5B polymerase inhibitor, is under development with Gilead Sciences for the once-daily, oral treatment of chronic hepatitis C. Oral sofosbuvir has been approved in the US for the treatment of chronic hepatitis C as a component...

  • US govt seals deals for smallpox, anthrax vax delivery.  // PharmacoEconomics & Outcomes News;6/11/2011, Issue 630, p15 

    The article reports that 2 million courses of smallpox antiviral, ST-246, is to be delivered by SIGA Technologies Inc. to the U.S. Strategic National Stockpile, under a recently signed contract with Biomedical Advanced Research and Development Authority of the Department of Health and Human...

  • WEEK IN REVIEW.  // BioWorld Insight;6/4/2012, Vol. 20 Issue 23, p5 

    The article offers biotechnology news briefs from the U.S. as of June 4, 2012. BioMarin Pharmaceutical Inc. has raised 248.8 million U.S. dollars through a public offering of its shares. A deal has been signed by Ensemble Therapeutics Corp. for drug discovery collaboration with Genentech Inc....

  • ImClone wins FDA approval for Erbitux.  // PharmaWatch: Biotechnology;April 2004, Vol. 3 Issue 4, p13 

    Reports on the approval of the U.S. Food and Drug Administration (FDA) to ImClone Systems Inc.'s Erbitux designated to treat advanced colorectal cancer. Impact of the approval of the FDA on the operation of the company; Evidence showing the safety and efficacy of Erbitux; Response of patients...

  • FDA approves Amgen's drug for chronic kidney disease.  // PharmaWatch: Biotechnology;April 2004, Vol. 3 Issue 4, p13 

    Reports on the approval of the U.S. Food and Drug Administration to Amgen Inc.'s Sensipar drug targeting chronic kidney disease. Classification of Sensipar; Safety and efficacy of the drug; Response of patients taking Sensipar.

  • Cell Therapeutics completes NDA submission for lymphoma drug.  // PharmaWatch: Biotechnology;Aug2009, Vol. 8 Issue 8, p13 

    The article reports on the completion of biopharmaceutical company Cell Therapeutics Inc. (CTI) to submit the new drug application (NDA) to the U.S. Food and Drug Administration (FDA) in the U.S. CTI reveals to accomplish the submission of NDA to the FDA for the use of pixantrone as a medication...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics